Skye Bioscience Inc
NASDAQ:SKYE

Watchlist Manager
Skye Bioscience Inc Logo
Skye Bioscience Inc
NASDAQ:SKYE
Watchlist
Price: 4.12 USD -1.2% Market Closed
Market Cap: 125m USD
Have any thoughts about
Skye Bioscience Inc?
Write Note

Skye Bioscience Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Skye Bioscience Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Skye Bioscience Inc
NASDAQ:SKYE
Cash from Operating Activities
-$20.9m
CAGR 3-Years
-49%
CAGR 5-Years
-30%
CAGR 10-Years
-36%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Skye Bioscience Inc
Glance View

Market Cap
125m USD
Industry
Biotechnology

Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.

SKYE Intrinsic Value
2.29 USD
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Skye Bioscience Inc's Cash from Operating Activities?
Cash from Operating Activities
-20.9m USD

Based on the financial report for Sep 30, 2024, Skye Bioscience Inc's Cash from Operating Activities amounts to -20.9m USD.

What is Skye Bioscience Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-36%

Over the last year, the Cash from Operating Activities growth was -40%. The average annual Cash from Operating Activities growth rates for Skye Bioscience Inc have been -49% over the past three years , -30% over the past five years , and -36% over the past ten years .

Back to Top